Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The antibody was designed and developed at Abzena’s Cambridge, UK,
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
